QuantaMatrix Inc. (KOSDAQ:317690)

Market Cap	77.72B
Revenue (ttm)	3.35B
Net Income (ttm)	-23.32B
Shares Out	19.58M
EPS (ttm)	-1,313.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	58,765
Average Volume	81,811
Open	3,975.00
Previous Close	3,970.00
Day's Range	3,860.00 - 4,045.00
52-Week Range	2,920.00 - 7,690.00
Beta	0.07
RSI	44.37
Earnings Date	Nov 14, 2025

About QuantaMatrix

QuantaMatrix Inc. operates as an in-vitro diagnostics company in South Korea. Its products include dRAST, a direct and rapid antimicrobial susceptibility test for treating sepsis that provides MIC-based phenotypic antimicrobial susceptibility testing direct from positive blood culture; QDST, a rapid phenotypic drug susceptibility testing system for tuberculosis; QPLEX Alz plus assay, an early diagnosis kit for Alzheimer's disease; and Quanti9 and QuantiGal, a prognostic prediction kit for cardiovascular diseases. QuantaMatrix Inc. was founded i...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 317690

Financial Performance

In 2024, QuantaMatrix's revenue was 2.50 billion, a decrease of -19.91% compared to the previous year's 3.12 billion. Losses were -20.17 billion, -6.44% less than in 2023.